Umd, Inc.

Femina Pharma Incorporated

Kimberly-clark Worldwide, Inc.

Giovanni M Pauletti

James H Liu

Wolfgang A Ritschel

Donald C Harrison

Chris Clendening

Steven Craig Gehling

Leslie Z Benet

Desai J Kishorkumar

Wolfgang A Ritschell

Michelle Wilson

Kishorkumar J Desai

Richard Soderstrom

A vaginal or buccal delivery of therapeutic agents having a substrate affinity for metabolic cytochrome P-450 enzymes and membrane efflux transporter systems. A method for augmentation of systemic exposure to the therapeutic agents having a substrate affinity for cytochrome P-450 enzymes and membrane efflux transporter systems, by delivering said agents to the systemic circulation through vaginal or buccal mucosa.

Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration

Compositions and methods for vaginal, buccal or nasal transmucosal delivery of drugs and for cryoprotecting of cells and embryos. For cryoprotection, the composition consisting essentially consist of a non-ionizable glycol derivative. For transmucosal delivery, the compositions essentially consist of a non-ionizable glycol derivative in a combination with a pharmaceutically active agent. For transmucosal delivery, the non-ionizable glycol derivative may be further combined with a mucoadhesive agent and/or a penetration enhancer and/or lipophilic or hydrophilic carrier for adhesion to and transport through a mucosa. The compositions are particularly suitable for administration of drugs through a nasal, buccal and vaginal mucosa or for long-term preservation of cell or embryos.

Compositions and method for transmucosal drug delivery and cryoprotection

A vaginal device for delivery of an anti-migraine or anti-nausea drug to the uterus and/or to the general circulation through vaginal mucosa. The device is at least partially coated with one or several layers of fluid impermeable material forming a cap, film, foam, foil or strip incorporated with mucoadhesive composition comprising the anti-migraine or anti-nausea drug.

Coated vaginal device for delivery of anti-migraine and anti-nausea drugs

A tampon adapted to deliver a therapeutic agent, the tampon including a tampon body having a distal end; and a dosage form affixed to the distal end of the tampon body, wherein the dosage form includes a formulation including a therapeutic agent, and wherein the dosage form comprises a plurality of layers. Also, a method for manufacturing a medicated tampon adapted to deliver a therapeutic agent, the method including manufacturing a tampon body having a distal end; producing a dosage form having a plurality of layers, wherein the dosage form includes a formulation including a therapeutic agent; and affixing the dosage form to the distal end of the tampon body.

Medicated tampon

Devices, methods, and compositions for cancer therapy by administration of chemotherapeutic agents and/or inhibitors of membrane efflux systems to the vagina for topical and systemic tumor targets.

Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy

Devices, methods, and improved formulation for transmucosal vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the systemic circulation using a vaginal device comprising an improved bisphosphonate formulation for transmucosal delivery. A method for treatment of osteoporosis and related bone and skeleton diseases, for prevention of bone breakdown and loss of bone mass and strength by intravaginal administration of bisphosphonates to the vagina and transmucosal delivery of bisphosphonates to the general circulation.

Formulations for transmucosal vaginal delivery of bisphosphonates

Devices, methods, and compositions for vaginal delivery of bisphosphonates. A targeted site delivery of bisphosphonates to the vagina using a medicated intravaginal device comprising a bisphosphonate composition formulated for transvaginal delivery. A method for treatment of osteoporosis and related bone and skeleton diseases, for prevention of bone breakdown and loss of bone mass and strength by intravaginal administration of bisphosphonates to the vagina and transvaginal delivery of bisphosphonates to the general circulation.

Growing community of inventors

Loveland, OH, United States of America

Giovanni M Pauletti